Measuring interictal burden among people affected by migraine: a descriptive survey study.
Measuring interictal burden among people affected by migraine: a descriptive survey study.
复制标题
DOI：
10.1186/s10194-022-01467-z
复制
发表时间：
2022-08-08
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
先前的研究广泛记录了偏头痛发作（“致命”）对患者健康相关生活质量的影响。很少有研究关注偏头痛对无偏头痛天数（“间歇期”）的影响。本研究旨在描述混合组偏头痛患者的偏头痛间期负担，并探讨与偏头痛间期负担相关的患者特征。在美国和德国招募偏头痛患者进行横断面在线调查，包括使用降钙素基因相关肽（CGRP）单克隆抗体（mAb）治疗的亚组。调查内容包括偏头痛间期负担量表（MIBS-4）、头痛影响测试（HIT-6）以及患者人口统计学、临床和治疗背景测量项目。数据分析采用描述性统计和线性回归。560名偏头痛患者完成了这项调查（美国：n = 257；德国：n = 249），其中195人服用了3个月或更长时间的CGRP单抗。参与者平均每月偏头痛天数（MMD）为8.5 (SD = 6.4)，每月头痛天数（MHD）为10.4 （SD = 7.1）。平均MIBS-4评分为6.3 (SD = 3.4)， 67%报告严重间期负担（MIBS-4:≥5）。平均HIT-6评分为65.3 (SD = 6.0)， 86%报告严重偏头痛影响（HIT-6:≥60）。MIBS-4与HIT-6 （r = 0.37）、MMD和MHD （r均= 0.27）相关。HIT-6、MMD、MHD、CGRP单抗治疗和抑郁症均与MIBS-4呈独立正相关。三分之二的研究样本报告了严重的间隔期负担。虽然间歇期负担与偏头痛的频率和偏头痛发作的影响有关，但研究结果也表明，它代表了总体疾病负担的一个独特方面。研究结果进一步表明，间歇期负担与抑郁症之间存在独特的关联。间期负担与CGRP单抗治疗之间的独特正相关表明，在接受CGRP单抗治疗的偏头痛患者中，仍有未满足的需求。
Previous research has extensively documented the impact of migraine episodes (‘ictal’) on patients’ health-related quality of life. Few studies have looked at the impact of migraine on migraine-free days (‘interictal’). This study was designed to describe interictal burden of migraine in a mixed group of people affected by migraine and to explore patient characteristics associated with interictal burden. People with migraine in the United States (US) and Germany were recruited for a cross-sectional online survey, including a subgroup treated with calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). The survey included the Migraine Interictal Burden Scale (MIBS-4), Headache Impact Test (HIT-6), and items measuring patient demographics, clinical and treatment background. Data were analyzed using descriptive statistics and linear regression. Five hundred six people with migraine completed the survey (US: n = 257; Germany: n = 249), of whom 195 had taken a CGRP mAb for three or more months. Participants had a mean of 8.5 (SD = 6.4) Monthly Migraine Days (MMD) and 10.4 (SD = 7.1) Monthly Headache Days (MHD). The mean MIBS-4 score was 6.3 (SD = 3.4), with 67% reporting severe interictal burden (MIBS-4: ≥5). The mean HIT-6 score was 65.3 (SD = 6.0), with 86% reporting severe migraine impact (HIT-6: ≥60). MIBS-4 was correlated with the HIT-6 (r = 0.37), MMD and MHD (both r = 0.27). The HIT-6, MMD, MHD, CGRP mAb treatment, and depression all had an independent positive association with the MIBS-4. Two-thirds of the study sample reported substantial interictal burden. Whilst interictal burden was associated with migraine frequency and impact of migraine attacks, study results also show it represented a distinct aspect of the overall disease burden. Study findings further indicate unique associations between interictal burden and depression. A unique positive association between interictal burden and CGRP mAb treatment suggests a remaining unmet need among people affected by migraine treated with CGRP mAb.
登录
查看更多内容
影响因子：
5
作者：
Blumenfeld, Andrew M.;Bloudek, Lisa M.;Lipton, Richard B.
通讯作者：
Lipton, Richard B.
影响因子：
7.4
作者：
Lampl, Christian;Thomas, Hallie;Steiner, Timothy J.
通讯作者：
Steiner, Timothy J.
影响因子：
5
作者：
Alex, Ashley;Vaughn, Caila;Rayhill, Melissa
通讯作者：
Rayhill, Melissa
影响因子：
5
作者：
Hareendran A;Skalicky A;Mannix S;Lavoie S;Desai P;Bayliss M;Thach AV;Mikol DD;Buse DC
通讯作者：
Buse DC
影响因子：
4
作者：
Doane, Michael J.;Gupta, Shaloo;Fang, Juanzhi
通讯作者：
Fang, Juanzhi